Insights to Impact:
A Selection of Our Recent Work

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

A ~$100M research tools and diagnostics company wanted to understand key applications and revenue potential of its novel technology to inform a go / no-go development decision

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

A leader in synthetic oligonucleotide manufacturing wanted to assess the total market size and opportunity

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings